EQUITY RESEARCH - RESULTS FLASH

SAFE FERTILITY GROUP



THAILAND / HEALTH CARE SERVICES



3Q24 results at first glance

กำไรสุทธิ 3Q24 ลดลง q-q, y-y จากรายได้และ margin ปรับลง ตามคาด Highlights

- SAFE รายงานกำไรสุทธิ 3Q24 ที่ 30 ล้านบาท ลดลง 34% q-q และ 50% y-y ใกล้เคียงที่เราคาด จากรายได้ค่าบริการตรวจพันธุกรรมตัวอ่อนและโครโมโซม ซะลอตัวต่อเนื่องจากการปรับลดค่าบริการเนื่องจากการแข่งขันด้านราคาสูงและ อัตราการฝากครรภ์ที่ลดลง และรายได้จาก IVF ลดลงจากจำนวนรอบการเก็บ ไข่ที่ลดลง ส่งผลให้อัตรากำไรขั้นตันหดตัว
- โดยรายได้รวมอยู่ที่ 193 ล้านบาท ลดลง 10% q-q และ 13% y-y จากจำนวน รอบของการเก็บไข่ลดลงมาอยู่ที่ 290 รอบ จาก 306 รอบใน 2Q24 และ 314 รอบใน 3Q23 โดยเฉพาะลูกค้าต่างชาติ เนื่องจากจำนวนนักท่องเที่ยวต่างชาติที่ ชะลอตัวและหลังจากจึนให้การอุดหนุนการทำ IVF ในประเทศตนเองในราคาที่ ไม่แพง ขณะที่รายได้จากการให้บริการตรวจพันธุกรรมตัวอ่อนและโครโมโชม 13% q-q, -19% y-y ตามคาด
- อัตรากำไรขั้นตันอยู่ที่ระดับ 52% ลดลงจาก 55.3% ใน 3Q24 และ 55.7% ใน 3Q23 จากจำนวนรอบเก็บไข่ที่ลดลงและรายได้จากการให้ตรวจโครโมโซมที่มี margin ลดลงมากและการปรับลดค่าบริการลง
- ค่าใช้จ่ายในการบริการและดำเนินงานลดลง q-q แต่เพิ่มขึ้น 19% y-y

Outlook

- แนวโน้มโมเมนตัมกำไร 4Q24 อาจพื้นตัว q-q จากตัวเลขยอดการเข้ารับการ รักษาเดือน ต.ค. ที่ผ่านมา พบว่าอยู่ในเกณฑ์ดี เพิ่มขึ้น m-m ขณะที่การ ให้บริการด้าน NGG (ตรวจพันธุกรรมคิดเป็น 20% ของรายได้รวม) ยังเผชิญกับ ภาวะการแข่งขันด้านราคาและอัตราการฝากครรภ์ที่ยังอยู่ในระดับต่ำ แม้บริษัท ได้นำเอาเทคโนโลยีใหม่เข้ามาให้บริการเสริมเพื่อดึงดูดลูกค้าเข้ามารักษา เพิ่มขึ้นแต่ยังไม่เห็นผลบวกที่ชัดเจน
- คงประมาณการกำไรสุทธิปี 2024 ที่ 195 ล้านบาท ลดลง 4.6% y-y แม้ราคาหุ้น ได้ปรับลงสะท้อนภาวะการแข่งขันของตลาด IVF ที่ชะลอตัว และการแข่งขัน ด้านราคาในการให้บริการตรวจโครโมโซม แต่ยังมี upside จำกัดจากราคา เป้าหมายปี 2025 ของเราที่ 14.70 บาท อิง PE 20 เท่า ใกล้เคียงกับค่าเฉลี่ย ของกลุ่ม Healthcare และบริษัทที่ทำธุรกิจ IVF ในต่างประเทศ ยังแนะนำ ถือ

TARGET PRICE THB14.70
CLOSE THB14.10
UP/DOWNSIDE +4.3%
TP vs CONSENSUS -25.1%

KEY STOCK DATA

| YE Dec (THB m) | 2023 | 2024E | 2025E | 2026E |
|----------------------|--------|--------|--------|--------|
| Revenue | 849 | 850 | 934 | 1,028 |
| Net profit | 204 | 195 | 213 | 231 |
| EPS (THB) | 0.67 | 0.64 | 0.70 | 0.76 |
| vs Consensus (%) | - | (10.5) | (16.5) | (24.0) |
| EBITDA | 302 | 307 | 368 | 443 |
| Recurring net profit | 204 | 195 | 213 | 231 |
| Core EPS (THB) | 0.67 | 0.64 | 0.70 | 0.76 |
| EPS growth (%) | (6.6) | (4.6) | 9.3 | 8.6 |
| Core P/E (x) | 21.0 | 22.0 | 20.1 | 18.5 |
| Dividend yield (%) | 1.1 | 1.9 | 1.8 | 2.0 |
| EV/EBITDA (x) | 10.3 | 10.0 | 8.5 | 7.2 |
| Price/book (x) | 2.6 | 2.4 | 2.2 | 2.2 |
| Net debt/Equity (%) | (71.1) | (68.2) | (59.9) | (56.6) |
| ROE (%) | 14.3 | 11.4 | 11.6 | 12.0 |



| Share price performance | 1 Month | 3 Month | 12 Month |
|--------------------------------|---------|------------|------------|
| Absolute (%) | (7.8) | (1.4) | (26.9) |
| Relative to country (%) | (8.9) | (13.4) | (30.0) |
| Mkt cap (USD m) | | | 125 |
| 3m avg. daily turnover (USD m) | | | 0.2 |
| Free float (%) | | | 26 |
| Major shareholder | Quangka | nanurug fa | mily (61%) |
| 12m high/low (THB) | | 2 | 3.70/13.60 |
| Issued shares (m) | | | 303.95 |

Sources: Bloomberg consensus; FSSIA estimates



Songklod Wongchai

Fundamental Investment Analyst on Securities; License no. 018086 songklod.won@fssia.com, +66 2646 9970

Exhibit 1: SAFE - 3Q24 results summary

| Profit & Loss Statement | 1Q23 | 2Q23 | 3Q23 | 4Q23 | 1Q24 | 2Q24 | 3Q24 | Chan | ge |
|-------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Year to Dec 31 | (THB m) | (q-q %) | (y-y %) |
| Revenue | 188 | 219 | 223 | 219 | 251 | 215 | 193 | (10) | (13) |
| Cost of services | 81 | 99 | 99 | 100 | 105 | 96 | 92 | (4) | (6) |
| Gross profit | 106 | 120 | 124 | 119 | 147 | 119 | 100 | (16) | (19) |
| Operating costs | 51 | 58 | 52 | 65 | 63 | 65 | 62 | (4) | 19 |
| Operating profit | 55 | 62 | 72 | 53 | 84 | 54 | 38 | (29) | (47) |
| Other income | 1 | 3 | 1 | 6 | 1 | 5 | 2 | n/a | n/a |
| Interest expense | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) | 18 |
| Profit before tax | 55 | 63 | 73 | 59 | 84 | 58 | 41 | (30) | (44) |
| Tax | (19) | (11) | (12) | (5) | (18) | (12) | (11) | (14) | (12) |
| Reported net profit | 36 | 52 | 61 | 54 | 67 | 46 | 30 | (34) | (50) |
| Key Ratios (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (ppt) | (ppt) |
| Gross margin | 56.7 | 54.7 | 55.7 | 54.2 | 58.4 | 55.3 | 52.0 | (3.3) | (3.6) |
| SG&A / Sales | 27.3 | 26.6 | 23.2 | 29.8 | 25.0 | 30.0 | 32.1 | 2.0 | 8.8 |
| Effective tax rate | 34.6 | 17.6 | 16.7 | 8.5 | 20.9 | 21.3 | 26.3 | 5.0 | 9.6 |

Sources: SAFE; FSSIA estimates

Exhibit 2: Peer comparison as of 7 Nov 2024

| Company | BBG | Market | EPS gı | rowth | PE | | R0 | DE | PB\ | / | Div \ | Yld |
|----------------------------|---------|---------|--------|-------|------|------|---------|---------|-----|------|-------|-----|
| | | Сар | 24E | 25E | 24E | 25E | 24E | 25E | 24E | 25E | 24E | 25E |
| | | (USD m) | (x) | (x) | (x) | (x) | (%) | (%) | (x) | (x) | (x) | (x) |
| Bangkok Dusit Med Service* | BDMS TB | 12,391 | 11.1 | 10.4 | 26.6 | 24.1 | 16.4 | 17.1 | 4.2 | 4.0 | 2.6 | 2.6 |
| Bumrungrad Hospital* | BH TB | 5,538 | 10.8 | 3.6 | 24.8 | 23.9 | 29.7 | 26.9 | 6.8 | 6.1 | 1.9 | 2.4 |
| Thonburi Healthcare Group* | THG TB | 457 | 69.6 | 60.1 | 31.3 | 19.6 | 4.9 | 7.6 | 1.5 | 1.5 | 2.2 | 3.6 |
| Ramkhamhaeng Hospital* | RAM TB | 822 | 20.1 | 17.8 | 16.8 | 14.3 | 8.9 | 10.0 | 1.5 | 1.4 | 3.0 | 3.5 |
| Bangkok Chain Hospital* | BCH TB | 1,207 | (0.7) | 16.0 | 29.6 | 25.5 | 10.9 | 12.0 | 3.2 | 3.0 | 2.1 | 1.9 |
| Chularat Hospital* | CHG TB | 911 | 15.0 | 15.4 | 26.0 | 22.5 | 15.5 | 16.7 | 3.9 | 3.6 | 2.3 | 2.7 |
| Praram 9 Hospital* | PR9 TB | 552 | 20.2 | 13.1 | 28.2 | 25.0 | 12.7 | 13.2 | 3.4 | 3.2 | 1.8 | 2.0 |
| Safe Fertility Group* | SAFE TB | 125 | (4.6) | 9.3 | 22.0 | 20.1 | 11.4 | 11.6 | 2.4 | 2.2 | 1.9 | 1.8 |
| Genesis Fertility Center* | GFC TB | 46 | 6.1 | 14.5 | 19.4 | 16.9 | 14.6 | 16.3 | 2.8 | 2.7 | 1.9 | 2.1 |
| Rajthanee Hospital | RJH TB | 203 | 12.8 | (7.6) | 14.6 | 15.8 | 21.4 | 19.6 | 3.2 | 3.0 | 4.8 | 4.6 |
| Ekachai Medical Care | EKH TB | 151 | 0.3 | (1.8) | 16.6 | 16.9 | 14.1 | 13.1 | 2.1 | 2.1 | 4.1 | 4.1 |
| Thailand average | | 22,404 | 14.6 | 13.7 | 23.3 | 20.4 | 14.6 | 14.9 | 3.2 | 3.0 | 2.6 | 2.8 |
| Regional | | | | | | | | | | | | |
| Ramsay Health care | RHC AU | 5,967 | 5.0 | 28.8 | 29.3 | 22.8 | 6.4 | 7.9 | 1.8 | 1.7 | 2.2 | 2.8 |
| Ryman Healthcare | RYM NZ | 2,047 | 373.0 | 22.3 | 14.1 | 11.5 | 6.8 | 6.4 | 0.7 | 0.7 | 0.0 | 0.0 |
| Amvis Holdings | 7071 JP | 1,227 | 55.6 | 21.4 | 20.0 | 16.5 | 24.8 | 23.9 | 4.4 | 3.5 | 0.3 | 0.3 |
| Raffles Medical Group | RFMD SP | 1,245 | (28.0) | 5.4 | 23.9 | 22.7 | 6.6 | 6.9 | 1.6 | 1.5 | 2.6 | 2.7 |
| Summerset Group | SUM NZ | 1,785 | 199.5 | 12.3 | 14.7 | 13.1 | 7.3 | 7.4 | 1.0 | 0.9 | 2.0 | 2.0 |
| Regis Health | REG AU | 1,316 | 334.9 | 29.3 | 39.2 | 30.3 | (172.4) | (113.4) | n/a | 64.8 | 2.3 | 2.7 |
| Charm Care Corp | 6062 JP | 268 | 22.3 | 9.5 | 8.6 | 7.9 | 21.2 | 21.2 | 1.8 | 1.5 | 2.7 | 3.0 |
| Monash IVF Group | MVF AU | 306 | 570.6 | 7.5 | 14.7 | 13.7 | 12.8 | 13.2 | 1.8 | 1.7 | 4.5 | 5.0 |
| Regional average | | 14,161 | 191.6 | 17.1 | 20.6 | 17.3 | (10.8) | (3.3) | 1.9 | 9.5 | 2.1 | 2.3 |
| Overall average | | 36,565 | 89.1 | 15.1 | 22.1 | 19.1 | 3.9 | 7.2 | 2.7 | 5.7 | 2.4 | 2.6 |

Sources: Bloomberg Consensus; *FSSIA estimates

Financial Statements

Safe Fertility Group

| Profit and Loss (THB m) Year Ending Dec | 2022 | 2023 | 2024E | 2025E | 2026E |
|---|-------|-------|-------|-------|-------|
| Revenue | 727 | 849 | 850 | 934 | 1,028 |
| Cost of goods sold | (329) | (380) | (387) | (425) | (468) |
| Gross profit | 397 | 469 | 463 | 509 | 560 |
| Other operating income | 0 | 0 | 0 | 0 | 0 |
| Operating costs | (194) | (226) | (226) | (252) | (277) |
| Operating EBITDA | 268 | 302 | 307 | 368 | 443 |
| Depreciation | (64) | (59) | (70) | (111) | (161) |
| Goodwill amortisation | 0 | 0 | 0 | 0 | 0 |
| Operating EBIT | 204 | 243 | 237 | 257 | 283 |
| Net financing costs | (3) | (3) | (3) | (3) | (3) |
| Associates | 0 | 0 | 0 | 0 | 0 |
| Recurring non-operating income | 3 | 10 | 6 | 8 | 5 |
| Non-recurring items | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 203 | 250 | 240 | 262 | 285 |
| Tax | (41) | (47) | (45) | (49) | (54) |
| Profit after tax | 162 | 203 | 195 | 213 | 231 |
| Minority interests | 0 | 1 | 0 | 0 | 0 |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 |
| Other items | 0 | 0 | 0 | 0 | 0 |
| Reported net profit | 162 | 204 | 195 | 213 | 231 |
| Non-recurring items & goodwill (net) | 0 | 0 | 0 | 0 | 0 |
| Recurring net profit | 162 | 204 | 195 | 213 | 231 |
| Per share (THB) | | | | | |
| Recurring EPS * | 0.72 | 0.67 | 0.64 | 0.70 | 0.76 |
| Reported EPS | 0.72 | 0.67 | 0.64 | 0.70 | 0.76 |
| DPS | 0.25 | 0.15 | 0.27 | 0.26 | 0.28 |
| Diluted shares (used to calculate per share data) | 225 | 304 | 304 | 304 | 304 |
| Growth | | | | | |
| Revenue (%) | 29.8 | 16.8 | 0.1 | 10.0 | 10.0 |
| Operating EBITDA (%) | 52.1 | 12.7 | 1.7 | 19.9 | 20.4 |
| Operating EBIT (%) | 104.1 | 19.4 | (2.6) | 8.4 | 10.0 |
| Recurring EPS (%) | 106.7 | (6.6) | (4.6) | 9.3 | 8.6 |
| Reported EPS (%) | 106.7 | (6.6) | (4.6) | 9.3 | 8.6 |
| Operating performance | | | | | |
| Gross margin inc. depreciation (%) | 54.7 | 55.3 | 54.5 | 54.5 | 54.5 |
| Gross margin exc. depreciation (%) | 63.6 | 62.2 | 62.8 | 66.4 | 70.2 |
| Operating EBITDA margin (%) | 36.9 | 35.6 | 36.2 | 39.4 | 43.2 |
| Operating EBIT margin (%) | 28.0 | 28.7 | 27.9 | 27.5 | 27.5 |
| Net margin (%) | 22.3 | 24.0 | 22.9 | 22.8 | 22.5 |
| Effective tax rate (%) | 20.3 | 18.9 | 18.9 | 18.9 | 18.9 |
| Dividend payout on recurring profit (%) | 34.6 | 22.3 | 41.9 | 36.6 | 36.8 |
| Interest cover (X) | 59.8 | 73.6 | 76.0 | 98.1 | 106.5 |
| nventory days | 57.0 | 64.8 | 75.1 | 75.7 | 77.5 |
| Debtor days | 8.0 | 9.4 | 10.0 | 9.6 | 9.5 |
| Creditor days | 89.0 | 86.1 | 99.0 | 72.0 | 46.6 |
| Operating ROIC (%) | 42.2 | 56.8 | 49.4 | 40.0 | 35.3 |
| ROIC (%) | 32.8 | 42.0 | 35.2 | 30.7 | 27.6 |
| ROE (%) | 14.1 | 14.3 | 11.4 | 11.6 | 12.0 |
| ROA (%) | 12.1 | 12.4 | 10.1 | 10.5 | 11.0 |
| * Pre exceptional, pre-goodwill and fully diluted | | | | | |
| Revenue by Division (THB m) | 2022 | 2023 | 2024E | 2025E | 2026E |
| Revenue from ICSI treatment | 609 | 667 | 650 | 715 | 787 |
| Revenue from genetic testing services for embryos and fetuses | 118 | 176 | 194 | 214 | 235 |
| Revenue from dermatology services | - | 6 | 5 | 5 | 6 |

Sources: Safe Fertility Group ; FSSIA estimates

Financial Statements

Safe Fertility Group

| Cash Flow (THB m) Year Ending Dec | 2022 | 2023 | 2024E | 2025E | 202 |
|--|--------------------|--------------|--------------|--------------|------|
| Recurring net profit | 162 | 204 | 195 | 213 | 2 |
| Depreciation | 64 | 59 | 70 | 111 | 1 |
| Associates & minorities | 6 | (1) | 0 | 0 | |
| Other non-cash items | 6 | (2) | 2 | 1 | |
| Change in working capital | 54 | 4 | (8) | (75) | (2 |
| Cash flow from operations | 292 | 264 | 259 | 250 | 3 |
| Capex - maintenance | (35) | (43) | (133) | (200) | (20 |
| Capex - new investment | 0 | 0 | 0 | 0 | |
| let acquisitions & disposals | (14) | (66) | (16) | (30) | (3 |
| Other investments (net) | 0 | 0 | 0 | 0 | |
| Cash flow from investing | (49) | (109) | (149) | (230) | (23 |
| Dividends paid | (56) | (46) | (82) | (78) | 3) |
| Equity finance | 3 | 291 | 6 | 0 | (9 |
| Debt finance | (7) | 0 | 0 | 0 | |
| Other financing cash flows | - | - | - | - | |
| ash flow from financing | (60) | 246 | (76) | (78) | (18 |
| Ion-recurring cash flows | - | _ | - | - | |
| Other adjustments | 0 | 0 | 0 | 0 | |
| let other adjustments | 0 | 0 | 0 | (8) | |
| Novement in cash | 183 | 401 | 34 | (66) | (3 |
| ree cash flow to firm (FCFF) | 246.69 | 158.16 | 112.55 | 22.74 | 143. |
| ree cash flow to equity (FCFE) | 236.13 | 155.18 | 109.35 | 11.85 | 146. |
| | | | | | |
| er share (THB) | 0.04 | 0.50 | 0.27 | 0.07 | ^ |
| CFF per share | 0.81 0.78 | 0.52 | 0.37 | 0.07 | 0. |
| CFE per share Recurring cash flow per share | 1.06 | 0.51 0.86 | 0.36 0.88 | 0.04 1.07 | 1. |
| Southing cash now per share | 1.00 | 0.00 | 0.00 | 1.07 | |
| alance Sheet (THB m) Year Ending Dec | 2022 | 2023 | 2024E | 2025E | 202 |
| angible fixed assets (gross) | 150 | 151 | 284 | 484 | 6 |
| ess: Accumulated depreciation | 0 | 0 | (54) | (149) | (29 |
| angible fixed assets (net) | 150 | 151 | 230 | 335 | 3 |
| tangible fixed assets (net) | 0 | 0 | 0 | 0 | |
| ong-term financial assets | 0 | 0 | 0 | 0 | |
| vest. in associates & subsidiaries | 0 | 0 | 0 | 0 | |
| ash & equivalents | 851 | 1,251 | 1,285 | 1,219 | 1,1 |
| /C receivable | 20 | 23 | 23 | 26 | ٠, |
| ventories | 49 | 65 | 65 | 65 | |
| Other current assets | 228 | 232 | 232 | 255 | 2 |
| current assets | 1,148 | 1,571 | 1,606 | 1,565 | 1,5 |
| Other assets | 114 | 171 | 171 | 188 | .,, |
| otal assets | 1,413 | 1,894 | 2,007 | 2,089 | 2, |
| common equity | 1,204 | 1,654 | 1,773 | 1,908 | 1,9 |
| linorities etc. | 6 | 1,054 | 4 | 1,908 | 1,3 |
| | | | | | 1,9 |
| otal shareholders' equity | 1,210 | 1,658 | 1,777 | 1,912 | 1,3 |
| ong term debt | 73 | 73 | 73 | 73 | |
| other long-term liabilities | 31 | 38 | 38 | 42 | |
| ong-term liabilities | 103 | 111 | 111 | 115 | • |
| /C payable | 66 | 85 | 87 | 37 | |
| hort term debt | 0 | 0 | 0 | 0 | |
| ther current liabilities | 33 | 40 | 33 | 33 | |
| urrent liabilities | 99 | 125 | 119 | 70 | |
| otal liabilities and shareholders' equity | 1,413 | 1,894 | 2,007 | 2,097 | 2, |
| et working capital | 198 | 195 | 201 | 276 | : |
| vested capital | 463 | 518 | 603 | 799 | |
| ncludes convertibles and preferred stock which is bei | ng treated as debt | | | | |
| er share (THB) | | | | | |
| ook value per share | 5.35 | 5.44 | 5.83 | 6.28 | 6 |
| angible book value per share | 5.35 | 5.44 | 5.83 | 6.28 | 6 |
| inancial strength | | | | | |
| et debt/equity (%) | (64.3) | (71.1) | (68.2) | (59.9) | (56 |
| et debt/equity (70) et debt/total assets (%) | (55.1) | (62.2) | (60.4) | (54.9) | (50 |
| urrent ratio (x) | 11.6 | 12.6 | 13.5 | 22.3 | (3 |
| F interest cover (x) | 69.3 | 46.1 | 35.2 | 5.4 | 5 |
| | | | | | |
| aluation | 2022 | 2023 | 2024E | 2025E | 202 |
| ecurring P/E (x) * | 19.6 | 21.0 | 22.0 | 20.1 | 1 |
| ecurring P/E @ target price (x) * | 20.5 | 21.9 | 23.0 | 21.0 | 1 |
| eported P/E (x) | 19.6 | 21.0 | 22.0 | 20.1 | 1 |
| ividend yield (%) | 1.8 | 1.1 | 1.9 | 1.8 | |
| rice/book (x) | 2.6 | 2.6 | 2.4 | 2.2 | |
| rice/tangible book (x) | 2.6 | 2.6 | 2.4 | 2.2 | |
| V/EBITDA (x) ** | 8.9 | 10.3 | 10.0 | 8.5 | |
| | 9.5 | 10.9 | 10.6 | 9.0 | |
| | | 10.5 | 10.0 | 5.0 | |
| V/EBITDA @ target price (x) ** V/invested capital (x) | 5.2 | 6.0 | 5.1 | 3.9 | |

Sources: Safe Fertility Group ; FSSIA estimates

Disclaimer for ESG scoring

| ESG score | Methodolog | ly . | | | | Rating | | | | | | |
|---|--|---|---|---|--|---|---|--|--|--|--|--|
| The Dow Jones Sustainability Indices (DJSI) By S&P Global | process base from the ann | ed on the com nual S&P Glob | transparent, rules-ban panies' Total Sustain al Corporate Sustain anies within each inc | nability nability | Scores resulting Assessment (CSA). | Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Glob ESG Score of less than 45% of the S&P Global ESG Score of the highes' scoring company are disqualified. The constituents of the DJSI indices ar selected from the Eligible Universe. | | | | | | |
| Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET) | managing bu Candidates I 1) no irregulation of >150 up capital. S 70%; 2) inde- wrongdoing | usiness with tr must pass the ar trading of the shareholders ome key disque ependent direct related to CG, | ility in Environmental cansparency in Governmental preemptive criteria, ne board members at a, and combined hold utility criteria inclustors and free float via, social & environmentarnings in red for > 3 | rnance with twand exed ling muade: 1) iolation ntal imp | , updated annually. o crucial conditions: cutives; and 2) free st be >15% of paid- CG score of below 3) executives' pacts; 4) equity in | To be eligible for THSI inclusion, verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. SETTHSI Index is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight maximum, and no cap for number of stocks. | | | | | | |
| CG Score by Thai Institute of Directors Association (Thai IOD) | annually by t Thailand (SE | the Thai IOD, | h in sustainable deve with support from the ts are from the persp s. | e Stock | Exchange of | Good (80-89), and not rated f equitable treati | 3 for Good (70 or scores belo ment of sharel 25%); 4) disclo | ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 osure & transpare | 60-69), 1 for P s include: 1) th 5% combined | ass (60-69), le rights; 2) and); 3) the role of | | |
| AGM level By Thai Investors Association (TIA) with support from the SEC | treatment and transparent and tof five the criteria cover date (45%), circulation of sexercised. The and verifiability | e incorporated and sufficiently e CG compon r AGM proced and after the r sufficient informa e second assess y; and 3) openne | es 1) the ease of attend | ations a importal d annual eting (4: first asso acilitating ding mee avolves t | and information is ant elements of two illy. The assessment 5%), at the meeting ssses 1) advance how voting rights can be tings; 2) transparency the meeting minutes that | pe | | | | | | |
| Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC) | establishmen policies. The (Companies di Declaration of Certification, in managers and | nt of key contr e Certification i eciding to becon Intent to kick off ncluding risk ass | Checklist include corrols, and the monitori is good for three yea are a CAC certified memif an 18-month deadline tressment, in place of poliablishment of whistleblo Il stakeholders.) | ing and ars. aber stan to submi licy and | developing of by submitting a t the CAC Checklist for control, training of | The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements. | | | | | | |
| Morningstar Sustainalytics | based on an risk is unma | assessment on aged. Sources | sk rating provides an of how much of a cor s to be reviewed include her media, NGO reports | mpany' corpora | s exposure to ESG ate publications and | more risk is un | managed, the | score is the sum higher ESG risk | is scored. | | | |
| | | ompany feedbac uality & peer rev | k, ESG controversies, is iews. | ssuer fee | edback on draft ESG | NEGL 0-10 | Low 10-20 | Medium 20-30 | High 30-40 | Severe 40+ | | |
| ESG Book | positioned to the principle helps explain over-weighti | o outperform o of financial m n future risk-ad | sustainable companioner the long term. The lateriality including in djusted performance the higher materiality basis. | he metl iformati . Mater | nodology considers on that significantly iality is applied by | The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance. | | | | | | |
| MSCI | MSCI ESG r | ratings aim to stry leaders ar | measure a company nd laggards accordin | r's man | agement of financially eir exposure to ESG ris | relevant ESG ris | ks and opport they manage | unities. It uses a those risks relat | rules-based m | nethodology to | | |
| | AAA | 8.571-10.00 | 0 | • | | | | | · | | | |
| | AA | 7.143-8.570 | Leader: | | leading its industry in ma | anaging the most s | ignificant ESG ri | sks and opportunitie | 28 | | | |
| | Α | 5.714-7.142 | 2 | | . , | | | | | | | |
| | BBB | 4.286-5.713 | Average: | | a mixed or unexceptional industry peers | onal track record of managing the most significant ESG risks and opportunities relative | | | | | | |
| | ВВ | 2.857-4.285 | | | - · | | | | | | | |
| | В | 1.429-2.856 | Laggard: | | lagging its industry base | d on its high expos | ure and failure t | o manage significar | nt ESG risks | | | |
| | ccc | 0.000-1.428 | 3 | | | | | | | | | |
| Moody's ESG solutions | believes that | t a company ir | | rs into | ke into account ESG ol its business model and edium to long term. | | | | | | | |
| Refinitiv ESG rating | based on pu | blicly available | e and auditable data. | . The s | company's relative ES core ranges from 0 to 0 to 25 = poor; >25 to 50 = | 100 on relative E | SG performar | nce and insufficie | nt degree of to | | | |
| S&P Global | | | | | ıring a company's perfo fication. The score ranç | | | of ESG risks, op | portunities, an | d impacts | | |
| Bloomberg | ESG Score | compared to its peers within the same industry classification. The score ranges from 0 to 100. ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best. | | | | | | | | | | |
| | | | of Pillar Scores, wi | icic ili | weights are determin | ed by the pillar p | nonty ranking | . valuoo rango ii | 0111 0 10 10, 10 | is the best. | | |

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Songklod Wongchai FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Songklod Wongchai started covering this stock from 08-Nov-2023

Price and TP are in local currency

Source: FSSIA estimates

| Company | Ticker | Price | Rating | Valuation & Risks |
|----------------------|---------|-----------|--------|---|
| Safe Fertility Group | SAFE TB | THB 14.10 | HOLD | ความเสี่ยงที่จะมีผลต่อประมาณการของเรา ได้แก่ เกิดเหตุพ้องร้องหรือ ร้องเรียนหากวิธีการรักษาเกิด ความผิดพลาด ลูกค้าต่างชาติลดลงจาก ผลกระทบของการเดินทาง หรือกรณีเกิดโรคระบาดใหม่ และ ต้นทุนค่ายาปรับตัวสูงขึ้นมากกว่าที่คาด |

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 07-Nov-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.